Cognitive functioning and brain MRI findings six months after acute COVID-19. A prospective observational study.

ingentiumby ingentium

In Coronavirus Literature.

Publication date: Jun 01, 2025

COVID-19 has been linked to many neurological complications, including cognitive impairment and findings in brain imaging. However, limited data exist regarding the link between magnetic resonance imaging (MRI) findings and cognitive functioning in COVID-19 patients. In this observational prospective study, we investigated the association between brain MRI findings, particularly cerebral microbleeds (CMBs) and white matter hyperintensities (WMHs), and cognitive functioning in COVID-19 survivors. Six months after acute COVID-19 diagnosed in 2020, 67 ICU-treated, 44 ward-treated, and 44 home-isolated patients, as well as 48 non-COVID-19 controls, underwent MRI and comprehensive neuropsychological evaluation. We applied multivariable linear regression models to investigate the independent associations of total cognitive score and domain scores separately with CMBs, WMHs and other factors. Age (p

Open Access PDF

Concepts Keywords
Home Cerebral microbleeds
Microbleeds Cognitive functioning
Models COVID-19
Mri Long-term
MRI

Semantics

Type Source Name
disease MESH COVID-19
disease MESH complications
disease MESH cognitive impairment
disease IDO history
disease MESH infarctions
disease MESH hemorrhage
disease MESH atrophy
drug DRUGBANK Coenzyme M
disease IDO susceptibility
disease MESH amyloid angiopathy
disease MESH Alzheimer’s disease
disease MESH syndrome
disease MESH cerebral edema
disease MESH incidental findings
disease MESH high blood pressure
disease MESH hyperlipidemia
disease MESH critical illness
disease MESH hypoxemia
disease MESH hemorrhagic stroke
disease MESH dementia
disease IDO process
drug DRUGBANK Oxygen
disease MESH stroke
disease MESH memory disorder
disease MESH contraindications
disease MESH claustrophobia
disease MESH acute disease
disease MESH infections
disease MESH hypercholesterolemia
drug DRUGBANK Methylergometrine
disease MESH abnormalities
disease MESH delayed memory
disease MESH neurological manifestations
disease MESH etiology
drug DRUGBANK Ibuprofen
disease MESH leukoencephalopathy
disease MESH clinical importance
disease IDO blood
disease MESH Neurocognitive Disorders
disease MESH Cardiovascular risk factors
disease MESH long COVID
disease MESH neuroinflammation
disease MESH acute respiratory distress syndrome
drug DRUGBANK Flunarizine

Original Article

(Visited 11 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *